<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">89961</article-id><article-id pub-id-type="doi">10.7554/eLife.89961</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Hybrid immunity from SARS-CoV-2 infection and vaccination in Canadian adults: cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-106850"><name><surname>Brown</surname><given-names>Patrick E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348852"><name><surname>Fu</surname><given-names>Sze Hang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322310"><name><surname>Newcombe</surname><given-names>Leslie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348854"><name><surname>Tang</surname><given-names>Xuyang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-2650"><name><surname>Nagelkerke</surname><given-names>Nico</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348855"><name><surname>Birnboim</surname><given-names>H Chaim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348856"><name><surname>Bansal</surname><given-names>Aiyush</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348866"><name><surname>Colwill</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348857"><name><surname>Mailhot</surname><given-names>Geneviève</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348858"><name><surname>Delgado-Brand</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348859"><name><surname>Tursun</surname><given-names>Tulunay</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348860"><name><surname>Qi</surname><given-names>Freda</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-8697"><name><surname>Gingras</surname><given-names>Anne-Claude</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6090-4437</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-181616"><name><surname>Slutsky</surname><given-names>Arthur S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-348861"><name><surname>Pasic</surname><given-names>Maria D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348862"><name><surname>Companion</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145957"><name><surname>Bogoch</surname><given-names>Isaac I</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-348863"><name><surname>Morawski</surname><given-names>Ed</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348864"><name><surname>Lam</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-348865"><name><surname>Reid</surname><given-names>Angus</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1017"><name><surname>Jha</surname><given-names>Prabhat</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7067-8341</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author"><collab>Ab-C Study Collaborators</collab></contrib><aff id="aff1"><institution content-type="dept">Centre for Global Health Research</institution>, <institution>University of Toronto</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff2"><institution content-type="dept">Sinai Health</institution>, <institution>Lunenfeld-Tanenbaum Research Institute</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff3"><institution>Unity Health Toronto</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff4"><institution content-type="dept">General Internal Medicine and Infectious Diseases</institution>, <institution>Toronto General Hospital</institution>, <addr-line><named-content content-type="city">Toronto</named-content></addr-line>, <country>Canada</country></aff><aff id="aff5"><institution>Angus Reid Institute</institution>, <addr-line><named-content content-type="city">Vancouver</named-content></addr-line>, <country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1086"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Reviewing editor</role><aff><institution>McGill University</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Prabhat.jha@utoronto.ca</email> (PJ);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>06</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e89961</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>20</day><month>06</month><year>2024</year></date></history><permissions><copyright-statement>© 2024, Brown et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Brown et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-89961-v1.pdf"/><abstract><p><bold>Background:</bold> Few national-level studies have evaluated the impact of 'hybrid' immunity (vaccination coupled with recovery from infection) from the Omicron variants of SARS-CoV-2.</p><p><bold>Methods:</bold> From May 2020 to December 2022, we conducted serial assessments (each of ~4000-9000 adults) examining SARS-CoV-2 antibodies within a mostly representative Canadian cohort drawn from a national online polling platform. Adults, most of whom were vaccinated, reported viral test-confirmed infections and mailed self-collected dried blood spots to a central lab. Samples underwent highly sensitive and specific antibody assays to spike and nucleocapsid protein antigens, the latter triggered only by infection. We estimated cumulative SARS-CoV-2 incidence prior to the Omicron period and during the BA.1/1.1 and BA.2/5 waves. We assessed changes in antibody levels and in age-specific active immunity levels.</p><p><bold>Results:</bold> Spike levels were higher in infected than in uninfected adults, regardless of vaccination doses. Among adults vaccinated at least thrice and infected more than six months earlier, spike levels fell notably and continuously for the nine months post-vaccination. By contrast, among adults infected within six months, spike levels declined gradually. Declines were similar by sex, age group, and ethnicity. Recent vaccination attenuated declines in spike levels from older infections. In a convenience sample, spike antibody and cellular responses were correlated. Near the end of 2022, about 35% of adults above age 60 had their last vaccine dose more than six months ago, and about 25% remained uninfected. The cumulative incidence of SARS-CoV-2 infection rose from 13% (95% CI 11-14%) before omicron to 78% (76-80%) by December 2022, equating to 25 million infected adults cumulatively. However, the COVID-19 weekly death rate during the BA.2/5 waves was less than half of that during the BA.1/1.1 wave, implying a protective role for hybrid immunity.</p><p><bold>Conclusions:</bold> Strategies to maintain population-level hybrid immunity require up-to-date vaccination coverage, including among those recovering from infection. Population-based, self-collected dried blood spots are a practicable biological surveillance platform.</p><p><bold>Funding:</bold> Funding was provided by the COVID-19 Immunity Task Force, Canadian Institutes of Health Research, Pfizer Global Medical Grants, and St. Michael's Hospital Foundation. PJ and ACG are funded by the Canada Research Chairs Program.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>COVID-19 Immunity Task Force</institution></institution-wrap></funding-source><award-id>2021-HQ-000139</award-id><principal-award-recipient><name><surname>Gingras</surname><given-names>Anne-Claude</given-names></name><name><surname>Jha</surname><given-names>Prabhat</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>EG2-179433</award-id><principal-award-recipient><name><surname>Jha</surname><given-names>Prabhat</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Pfizer Global Medical Grants</institution></institution-wrap></funding-source><award-id>61608943</award-id><principal-award-recipient><name><surname>Jha</surname><given-names>Prabhat</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100015150</institution-id><institution>St. Michael's Hospital Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jha</surname><given-names>Prabhat</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Arthur S Slutsky, Has received consulting fees from Apeiron Biologics, Cellenkos, Diffusion Pharmaceuticals, and GlaxoSmithKline outside the submitted work..</p></fn><fn fn-type="conflict" id="conf3"><p>Isaac I Bogoch, Has served as a consultant for BlueDot and the National Hockey League Players' Association outside the submitted work..</p></fn><fn fn-type="conflict" id="conf4"><p>Prabhat Jha, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The Ab-C study was approved by the Unity Health Toronto Research Ethics Board (REB # 20-107 and 21-213). All participants provided informed consent to be included in the study.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Ab-C data will be made available publicly through the COVID-19 Immunity Task Force (CITF) Databank. To access the data, please create an account on the CITF Databank portal and submit an application to use the data. Your application will be reviewed by the CITF Databank team. The data access procedure is described in detail at https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/11/data-access-diagram-en.pdf. This process is free of charge.Analytical code will be available on request in accordance with the Ab-C study's data governance plan. Please email the corresponding author, Dr. Jha at prabhat.jha@utoronto.ca to request the code. The CITF data team harmonizes data from multiple studies funded by CITF, including the Ab-C study. As a result, variable names and labels may change after the harmonization. To minimize confusion when using the code, it's best to have some contact with us when using the harmonized data.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>COVID-19 Immunity Task Force</collab></person-group><year iso-8601-date="2022">2022</year><source>CITF Data Portal</source><ext-link ext-link-type="uri" xlink:href="https://portal.citf.mcgill.ca/">https://portal.citf.mcgill.ca/</ext-link><comment>(CITF) Databank</comment></element-citation></p></sec></sec></back></article>